CN107106873A - 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 - Google Patents

用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 Download PDF

Info

Publication number
CN107106873A
CN107106873A CN201680004801.2A CN201680004801A CN107106873A CN 107106873 A CN107106873 A CN 107106873A CN 201680004801 A CN201680004801 A CN 201680004801A CN 107106873 A CN107106873 A CN 107106873A
Authority
CN
China
Prior art keywords
inhibitor
oxygen
nitrogen
sulphur
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680004801.2A
Other languages
English (en)
Chinese (zh)
Inventor
G.C.哈里曼
R.卡佩勒-利伯曼
W.F.韦斯特林
H.J.哈伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geely De Appollo
Original Assignee
Geely De Appollo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geely De Appollo filed Critical Geely De Appollo
Publication of CN107106873A publication Critical patent/CN107106873A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680004801.2A 2015-01-09 2016-01-08 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 Pending CN107106873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
US62/101,726 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
CN107106873A true CN107106873A (zh) 2017-08-29

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680004801.2A Pending CN107106873A (zh) 2015-01-09 2016-01-08 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗

Country Status (13)

Country Link
US (2) US20180021341A1 (https=)
EP (2) EP3242722A4 (https=)
JP (2) JP2018501276A (https=)
KR (1) KR20170102299A (https=)
CN (1) CN107106873A (https=)
AU (1) AU2016205138A1 (https=)
BR (1) BR112017014341A2 (https=)
CA (1) CA2972919A1 (https=)
EA (2) EA201791258A1 (https=)
HK (2) HK1243369A1 (https=)
MX (1) MX2017008844A (https=)
SG (1) SG11201705361PA (https=)
WO (1) WO2016112305A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
CN109745549A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN110628810A (zh) * 2019-08-13 2019-12-31 浙江大学 一种提高植物光合效率的方法
CN110950884A (zh) * 2018-09-27 2020-04-03 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
WO2020103851A1 (zh) * 2018-11-20 2020-05-28 中国医药研究开发中心有限公司 螺环类化合物及其医药用途
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CN113164498A (zh) * 2018-09-06 2021-07-23 盖尔梅德研究与发展有限公司 用于肝病的治疗的组合疗法
CN116490189A (zh) * 2020-11-17 2023-07-25 伊文蒂瓦公司 用于肝病治疗的联合疗法
CN117396206A (zh) * 2021-06-04 2024-01-12 吉利德科学公司 治疗nash和nafld的化合物

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
AU2016361412A1 (en) * 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
SG11201807077RA (en) 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP4553082A3 (en) 2016-11-04 2025-08-20 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
JP2019537607A (ja) * 2016-11-10 2019-12-26 ガルメド リサーチ アンド ディベロップメント リミテッド 非アルコール性脂肪性肝疾患の患者における線維化の抑制
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CA3043284C (en) * 2016-11-10 2022-06-28 Galmed Research And Development Ltd. Treatment for fibrosis
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3571205B1 (en) * 2017-01-22 2023-08-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
US11142531B2 (en) 2017-03-24 2021-10-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
JP2020512342A (ja) * 2017-03-28 2020-04-23 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
SI4122464T1 (sl) * 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
JP2020516627A (ja) * 2017-04-12 2020-06-11 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
JP7266531B2 (ja) * 2017-04-18 2023-04-28 ジェンフィ エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
US11583570B2 (en) * 2017-04-24 2023-02-21 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
US20200129511A1 (en) * 2017-06-19 2020-04-30 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
CN111201234A (zh) * 2017-07-17 2020-05-26 南京瑞捷医药科技有限公司 新型化合物及其作为acc抑制剂的用途
TW201910338A (zh) * 2017-07-26 2019-03-16 大陸商南京聖和藥業股份有限公司 作為acc抑制劑的化合物及其應用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
NZ766594A (en) 2018-01-31 2025-12-19 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019209738A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP4678727A3 (en) 2018-07-26 2026-03-11 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
US12600943B2 (en) 2019-02-01 2026-04-14 The University Of Hong Kong Innervated organoid compositions and methods of making same
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
JP7631217B2 (ja) * 2019-04-10 2025-02-18 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3995498A4 (en) * 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
BR112022001488A2 (pt) 2019-07-29 2022-04-19 Heparegenix Gmbh Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
WO2021040440A1 (ko) * 2019-08-30 2021-03-04 (주)셀트리온 비알콜성 지방간염(nash, nonalcoholic steatohepatitis) 치료 또는 예방을 위한 약학 조성물
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
CA3168474A1 (en) * 2020-03-11 2021-09-16 Mi-Kyung Kim Pharmaceutical composition for prevention or treatment of nonalcoholic steatohepatitis
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4154880A4 (en) * 2020-05-21 2024-06-05 Shionogi & Co., Ltd Pharmaceutical for treating fatty liver diseases
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4681774A3 (en) 2021-03-29 2026-03-25 Gilead Sciences, Inc. Khk inhibitors
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
JPWO2023090411A1 (https=) 2021-11-19 2023-05-25
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
WO2025225969A1 (ko) * 2024-04-22 2025-10-30 연세대학교 원주산학협력단 CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525194A (ja) * 2008-06-20 2011-09-15 キネメッド， インコーポレイテッド 線維性疾患または病態を治療するための組成物
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
JP6417402B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AU2014262547A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994139B1 (en) * 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
CN104105485A (zh) * 2011-11-11 2014-10-15 尼普斯阿波罗有限公司 Acc抑制剂和其用途

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
CN109745549A (zh) * 2017-11-06 2019-05-14 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
CN113164498A (zh) * 2018-09-06 2021-07-23 盖尔梅德研究与发展有限公司 用于肝病的治疗的组合疗法
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN110950884A (zh) * 2018-09-27 2020-04-03 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
WO2020103851A1 (zh) * 2018-11-20 2020-05-28 中国医药研究开发中心有限公司 螺环类化合物及其医药用途
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
CN110628810A (zh) * 2019-08-13 2019-12-31 浙江大学 一种提高植物光合效率的方法
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
CN116490189A (zh) * 2020-11-17 2023-07-25 伊文蒂瓦公司 用于肝病治疗的联合疗法
CN117396206A (zh) * 2021-06-04 2024-01-12 吉利德科学公司 治疗nash和nafld的化合物

Also Published As

Publication number Publication date
EA201892625A1 (ru) 2019-07-31
EP3242722A4 (en) 2018-07-11
BR112017014341A2 (pt) 2018-03-27
US20190381045A1 (en) 2019-12-19
KR20170102299A (ko) 2017-09-08
HK1246232A1 (zh) 2018-09-07
MX2017008844A (es) 2018-03-14
AU2016205138A1 (en) 2017-07-13
EA201791258A1 (ru) 2017-12-29
HK1243369A1 (zh) 2018-07-13
SG11201705361PA (en) 2017-08-30
EP3597271A1 (en) 2020-01-22
JP2018501276A (ja) 2018-01-18
WO2016112305A1 (en) 2016-07-14
EP3242722A1 (en) 2017-11-15
JP2020109130A (ja) 2020-07-16
US20180021341A1 (en) 2018-01-25
CA2972919A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
CN107106873A (zh) 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
JP7335056B2 (ja) ビグアナイド組成物および代謝障害を治療する方法
US11963961B2 (en) Combination therapy comprising an ACC inhibitor
JP6581625B2 (ja) 代謝障害を治療するための組成物および方法
JP2004525179A (ja) ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置
US9480663B2 (en) Biguanide compositions and methods of treating metabolic disorders
US20090149498A1 (en) Pharmaceutical composition having prokinetic effect
HK40021469A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
HK40024982A (en) Combination therapy comprising an acc inhibitor
EA042749B1 (ru) Композиции метформина и способы лечения расстройств метаболизма глюкозы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243369

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1243369

Country of ref document: HK